Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. by Couch, Fergus J. et al.
Common variants at the 19p13.1 and ZNF365 loci are associated
with ER subtypes of breast cancer and ovarian cancer risk in
BRCA1 and BRCA2 mutation carriers
Fergus J. Couch1,#, Mia M. Gaudet2,#, Antonis C. Antoniou3, Susan J. Ramus4, Karoline B.
Kuchenbaecker3, Penny Soucy5, Jonathan Beesley6, Xiaoqing Chen6, Xianshu Wang1,
Tomas Kirchhoff7, Lesley McGuffog3, Daniel Barrowdale3, Andrew Lee3, Sue Healey6, Olga
M. Sinilnikova8,9, Irene L. Andrulis10,11,12, Hilmi Ozcelik11, Anna Marie Mulligan11,13, for
OCGN, Mads Thomassen14, Anne-Marie Gerdes15, Uffe Birk Jensen16, Anne-Bine Skytte17,
Torben A. Kruse14, Maria A. Caligo18, Anna von Wachenfeldt19, Gisela Barbany-Bustinza20,
Niklas Loman21, Maria Soller22, Hans Ehrencrona23, Per Karlsson24, for SWE-BRCA,
Katherine L. Nathanson25, Timothy R. Rebbeck26, Susan M. Domchek25, Ania
Jakubowska27, Jan Lubinski27, Katarzyna Jaworska27,28, Katarzyna Durda27, Elżbieta
Złowocka27, Tomasz Huzarski27, Tomasz Byrski27, Jacek Gronwald27, Cezary Cybulski27,
Bohdan Górski27, Ana Osorio29, Mercedes Durán30, María Isabel Tejada31, Javier Benitez32,
Ute Hamann33, Frans B.L. Hogervorst34, Theo A. van Os35, Flora E. van Leeuwen36, Hanne
E.J. Meijers-Heijboer37, Juul Wijnen38, Marinus J. Blok39, Marleen Kets40, Maartje J.
Hooning41, Rogier A. Oldenburg42, Margreet G.E.M. Ausems43, for HEBON, Susan Peock3,
Debra Frost3, Steve D. Ellis3, Radka Platte3, Elena Fineberg3, D. Gareth Evans44, Chris
Jacobs45, Rosalind A. Eeles46, Julian Adlard47, Rosemarie Davidson48, Diana M. Eccles49,
Trevor Cole50, Jackie Cook51, Joan Paterson52, Carole Brewer53, Fiona Douglas54, Shirley
V. Hodgson55, Patrick J. Morrison56, Lisa Walker57, Mary E. Porteous58, M. John
Kennedy59, Lucy E. Side60, for EMBRACE, Betsy Bove61, Andrew K. Godwin62, Dominique
Stoppa-Lyonnet63,64,65,66, Marion Fassy-Colcombet66, Laurent Castera66, François
Cornelis67,68,69, Sylvie Mazoyer9, Mélanie Léoné8, Nadia Boutry-Kryza8, Brigitte Bressac-de
Paillerets70, Olivier Caron71, Pascal Pujol72, Isabelle Coupier72, Capucine Delnatte73, Linda
Akloul73, Henry T. Lynch74, Carrie L. Snyder74, for GEMO Study Collaborators, Saundra S.
Buys75, Mary B. Daly76, MaryBeth Terry77, Wendy K. Chung77, Esther M. John78, Alexander
Miron79, Melissa C. Southey80, John L. Hopper81, David E. Goldgar82, Christian F. Singer83,
Christine Rappaport83, Muy-Kheng M. Tea83, Anneliese Fink-Retter83, Thomas V. O.
Hansen84, Finn C. Nielsen84, Aðalgeir Arason85,86, Joseph Vijai7, Sohela Shah7, Kara
Sarrel7, Mark E. Robson7, Marion Piedmonte87, Kelly Phillips88, Jack Basil89, Wendy S.
Rubinstein90,91, John Boggess92, Katie Wakeley93, Amanda Ewart-Toland94, Marco
Montagna95, Simona Agata95, Evgeny N. Imyanitov96, Claudine Isaacs97, Ramunas
Janavicius98, Conxi Lazaro99, Ignacio Blanco100, Lidia Feliubadalo99, Joan Brunet100,
Simon A Gayther101, Paul PD Pharoah102, Kunle O. Odunsi103, Beth Y. Karlan104, Christine
S. Walsh104, Edith Olah105, Soo Hwang Teo105, Patricia A. Ganz107, Mary S. Beattie108,
Elizabeth J. van Rensburg109, Cecelia M. Dorfling109, Orland Diez110, Ava Kwong111, Rita K.
Schmutzler112, Barbara Wappenschmidt112, Christoph Engel113, Alfons Meindl114, Nina
Corresponding Author: Fergus Couch, Mayo Clinic, Stabile 2-42, 200 First Street SW, Rochester, MN 55905, USA; Tel:
507-284-3623; Fax: 507-538-1937; couch.fergus@mayo.edu.
#F.J. Couch and M.M. Gaudet contributed equally as primary authors.
*K. Offit and J. Simard contributed equally as senior authors
Disclosure of Potential Conflicts of Interest
The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the
collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the
US Government or the BCFR. No potential conflicts of interest are disclosed.
NIH Public Access
Author Manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 October 01.
Published in final edited form as:
Cancer Epidemiol Biomarkers Prev. 2012 April ; 21(4): 645–657. doi:10.1158/1055-9965.EPI-11-0888.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ditsch115, Norbert Arnold116, Simone Heidemann117, Dieter Niederacher118, Sabine
Preisler-Adams119, Dorothea Gadzicki120, Raymonda Varon-Mateeva121, Helmut
Deissler122, Andrea Gehrig123, Christian Sutter124, Karin Kast125, Britta Fiebig126, Wolfram
Heinritz127, Trinidad Caldes128, Miguel de la Hoya128, Taru A. Muranen129, Heli
Nevanlinna129, Marc D. Tischkowitz130,131, Amanda B. Spurdle6, Susan L. Neuhausen132,
Yuan Chun Ding132, Noralane M. Lindor133, Zachary Fredericksen134, V. Shane Pankratz134,
Paolo Peterlongo135, Siranoush Manoukian136, Bernard Peissel136, Daniela Zaffaroni136,
Monica Barile137, Loris Bernard138, Alessandra Viel139, Giuseppe Giannini140, Liliana
Varesco141, Paolo Radice135, Mark H. Greene142, Phuong L. Mai142, Douglas F. Easton3,
Georgia Chenevix-Trench6, for kConFab investigators, Kenneth Offit7,*, and Jacques
Simard5,* on behalf of the Consortium of Investigators of Modifiers of BRCA1/2
1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
2Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA 3Centre for
Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of
Cambridge, UK 4Department of Preventive Medicine, Keck School of Medicine, University of
Southern California, CA, USA 5Canada Research Chair in Oncogenetics, Cancer Genomics
Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City
(Quebec), Canada 6Department of Genetics, Queensland Institute of Medical Research,
Brisbane, Australia 7Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer
Center, New York, NY, USA 8Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents,
Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France 9INSERM U1052,
CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon,
France 10Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5,
Cancer Care Ontario, Department of Molecular Genetics, University of Toronto, Ontario, Canada
11Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Cancer
Care Ontario, Department of Laboratory Medicine and Pathobiology, University of Toronto,
Ontario, Canada 12Ontario Cancer Genetics Network: Cancer Care Ontario, Canada
13Department of Laboratory Medicine, and the Keenan Research Centre of the Li Ka Shing
Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada 14Department of Clinical
Genetics, Odense University Hospital, Odense, Denmark 15Department of Clincial Genetics,
Rigshospitalet, København, Denmark 16Department of Clinical Genetics, Skejby Hospital, Århus,
Denmark 17Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark 18Section of Genetic
Oncology, University Hospital of Pisa, Pisa, Italy 19Department of Oncology, Karolinska University
Hospital, Stockholm, Sweden 20Department of Clinical Genetics, Karolinska University Hospital,
Stockholm, Sweden 21Department of Oncology, Lund University Hospital, Lund, Sweden
22Department of Clinical Genetics. Lund University Hospital, Lund, Sweden 23Department of
Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
24Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden 25Department
of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA 26Department of Biostatistics and Epidemiology, Abramson
Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA,
USA 27Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
28Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland
29Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer
Research Centre, and Spanish Network on Rare Diseases (CIBERER), Madrid, Spain 30Institute
of Biology and Molecular Genetics. Universidad de Valladolid (IBGM-UVA), Valladolid, Spain
31Molecular Genetics Laboratory (Department of Biochemistry), Cruces Hospital Barakaldo,
Bizkaia, Spain 32Human Genetics Group and Genotyping Unit, Human Cancer Genetics
Programme, Spanish National Cancer Research Centre, and Spanish Network on Rare Diseases
(CIBERER), Madrid, Spain 33Molecular Genetics of Breast Cancer, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, Germany 34Family Cancer Clinic, Netherlands
Couch et al. Page 2
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Cancer Institute, Amsterdam, The Netherlands 35Department of Clinical Genetics, Academic
Medical Center, Amsterdam, The Netherlands 36Department of Epidemiology. Head, Division of
Psychosocial Research & Epidemiology, Netherlands Cancer Institute, Amsterdam, The
Netherlands 37Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands
38Department of Human Genetics & Department of Clinical Genetics, Leiden University Medical
Center, Leiden, The Netherlands 39Department of Genetics and Cell Biology, University Medical
Center, Maastricht, The Netherlands 40Hereditary Cancer Clinic, Radboud University Nijmegen
Medical Center, The Netherlands 41Department of Medical Oncology, Family Cancer Clinic,
Erasmus University Medical Center, Rotterdam, The Netherlands 42Department of Clinical
Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands
43Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
44Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester
University Hospitals NHS Foundation Trust, Manchester, UK 45Clinical Genetics, Guy’s and St.
Thomas’ NHS Foundation Trust, London, UK 46Oncogenetics Team, The Institute of Cancer
Research and Royal Marsden NHS Foundation Trust, UK 47Yorkshire Regional Genetics Service,
Leeds, UK 48Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, UK
49University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust,
Southampton UK 50West Midlands Regional Genetics Service, Birmingham Women’s Hospital
Healthcare NHS Trust, Edgbaston, Birmingham, UK 51Sheffield Clinical Genetics Service,
Sheffield Children’s Hospital, Sheffield, UK 52Department of Clinical Genetics, East Anglian
Regional Genetics Service, Addenbrookes Hospital, Cambridge, UK 53Department of Clinical
Genetics, Royal Devon & Exeter Hospital, Exeter, UK 54Institute of Genetic Medicine, Centre for
Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK 55Medical Genetics
Unit, St George's, University of London, UK 56Northern Ireland Regional Genetics Centre, Belfast
Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast,
Belfast UK 57Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK 58South East of
Scotland Regional Genetics Service, Western General Hospital, Edinburgh, UK 59Academic Unit
of Clinical and Molecular Oncology, Trinity College Dublin and St James's Hospital, Dublin,
Ireland 60North East Thames Regional Genetics Service, Great Ormond Street Hospital for
Children NHS Trust, London, UK 61Clinical Molecular Genetics Laboratory, Fox Chase Cancer
Center, Philadelphia, PA, USA 62Department of Pathology and Laboratory Medicine, University of
Kansas Medical Center, Kansas City, KS, USA 63GEMO Study Collaborators: Cancer Genetics
Network “Groupe Génétique et Cancer”, Fédération Nationale des Centres de Lutte Contre le
Cancer, France 64Service de Génétique Oncologique, Institut Curie, Paris, France 65Unité
INSERM U830, Institut Curie, Paris, France 66Université Paris Descartes, Faculté de Médecine,
Paris, France 67Genetic Unit, Avicenne Hospital, Assitance Publique-Hôpitaux de Paris, Paris,
France 68Sud-Francilien Hospital, Evry-Corbeil, France 69University Hospital, Clermont-Ferrand,
France 70Genetics Department, Institut de Cancérologie Gustave Roussy, Villejuif, France
71Consultation de Génétique, Département de Médecine, Institut de Cancérologie Gustave
Roussy, Villejuif, France 72Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier,
France 73Service Oncologie Médicale, Centre René Gauducheau, Nantes, France 74Department
of Preventive Medicine, Creighton University, Omaha, NE, USA 75Department of Oncological
Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA 76Fox Chase
Cancer Center, Philadelphia, PA, USA 77Department of Epidemiology, Columbia University, New
York, NY, USA 78Department of Epidemiology, Cancer Prevention Institute of California, Fremont,
CA, USA 79Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA
80Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne,
Parkville, Victoria, Australia 81Centre for Molecular, Environmental, Genetic and Analytic
Epidemiology, University of Melbourne, Melbourne, Victoria, Australia 82Department of
Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA 83Department of
OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Couch et al. Page 3
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
84Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9,
Copenhagen, Denmark 85Department of Pathology, Landspitali University Hospital, Reykjavik,
Iceland 86Faculty of Medicine, University of Iceland, Reykjavik, Iceland 87Gynecologic Oncology
Group Statistical and Data Center, Roswell Park Cancer Institute, 666 Elm St, Buffalo, NY, USA
88Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
and Department of Medicine, St Vincent’s Hospital, The University of Melbourne, Victoria,
Australia 89Good Samaritan Hospital, Department of Obstetrics and Gynecology, GOG affilitate
90Center for Medical Genetics, NorthShore University Health System, Evanston, IL, USA
91Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
92University of North Carolina, Chapel Hill, NC, USA 93Dana-Farber/Brigham and Women's
Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, MA, USA
94Departments of Molecular Virology, Immunology & Medical Genetics and Internal Medicine,
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA 95Istituto
Oncologico Veneto IOV - IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy
96Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia
97Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center,
Georgetown University, Washington D.C., USA 98Dept. of Molecular and Regenerative medicine,
Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu
Clinics, Santariskiu st. 2, Vilnius, Lithuania 99Molecular Diagnostic Unit, Hereditari Cancer
Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain 100Genetic Counseling Unit,
Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain
101Department of Preventive Medicine, Keck School of Medicine, University of Southern
California, CA, USA 102Department of Oncology, University of Cambridge, Cambridge, UK
103Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
104Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Medical Center, Los Angeles, CA, USA 105Department of Molecular Genetics, National Institute of
Oncology, Budapest, Hungary 106Breast Cancer Research Unit, University Malaya Cancer
Research Institute, University Malaya, Malaysia and Cancer Research Initiatives Foundation,
Sime Darby Medical Centre, Subang Jaya, Malaysia 107UCLA School of Public Health,
Department of Health Services, Los Angeles, CA, USA 108Department of Medicine, Epidemiology
and Biostatistics, University of California, San Francisco, CA, USA 109Cancer Genetics
Laboratory, Department of Genetics, University of Pretoria, South Africa 110Molecular Medicine
and Genetics Program. Vall d'Hebron University Hospital. Oncogenetics Laboratory. Vall
d'Hebron Institute of Oncology (VHIO). Barcelona, Spain 111Hong Kong Hereditary Breast Cancer
Family Registry and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong
112Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and
Centre for Integrated Oncology (CIO), University hospital of Cologne, Germany 113Institute for
Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany 114Department
of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical
University Munich, Germany 115Department of Gynaecology and Obstetrics, Ludwig-Maximilian
University Munich, Germany 116Department of Gynaecology and Obstetrics, University Hospital of
Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Germany 117Institute of
Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts
University Kiel, Germany 118Department of Gynaecology and Obstetrics, University Hospital
Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany 119Institute of Human Genetics,
University of Münster, Münster, Germany 120Institute of Cell and Molecular Pathology, Hannover
Medical School, Hannover, Germany 121Institute of Human Genetics, Campus Virchov Klinikum,
Berlin, Germany 122Department of Gynaecology and Obstetrics, University Hospital Ulm,
Germany 123Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics,
Institute of Human Genetics, University Würzburg, Germany 124Institute of Human Genetics,
Division of Molecular Genetics, University Heidelberg, Germany 125Department of Gynaecology
Couch et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Germany
126Institute of Human Genetics, University Regensburg, Germany 127Institute of Human Genetics,
University Leipzig, Germany 128Molecular Oncology Laboratory, Hospital Clinico San Carlos.
Martin Lagos s/n, 28040 Madrid, Spain 129Department of Obstetrics and Gynecology, University
of Helsinki and Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland
130Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill
University, Montreal, Quebec, Canada 131Lady Davis Institute, Segal Cancer Centre, Jewish
General Hospital, Montreal, Quebec, Canada 132Department of Population Sciences, Beckman
Research Institute of City of Hope, Duarte, CA USA 133Department of Medical Genetics, Mayo
Clinic Rochester, MN, USA 134Department of Health Sciences Research, Mayo Clinic, Rochester,
MN, USA 135Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of
Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), and
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy 136Unit of Medical Genetics,
Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori
(INT), Milan, Italy 137Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia
(IEO), Milan, Italy 138Department of Experimental Oncology, Istituto Europeo di Oncologia, and
Consortium for Genomics Technology (Cogentech), Milan, Italy 139Unit of Experimental Oncology
1, Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy 140Department of Experimental
Medicine, University La Sapienza, Rome, Italy 141Unit of Hereditary Cancer, Department of
Epidemiology, Prevention and Special Functions, Istituto Nazionale per la Ricerca sul Cancro
(IST), Genoa, Italy 142Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics,
NCI, Rockville, MD, USA
Abstract
Background—Genome-wide association studies (GWAS) identified variants at 19p13.1 and
ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers,
respectively. We explored associations with ovarian cancer and with breast cancer by tumor
histopathology for these variants in mutation carriers from the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA).
Methods—Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40
studies were combined.
Results—We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for
BRCA1 mutation carriers (hazard ratio (HR)=1.17; 95%CI 1.07–1.27; p=7.42×10−4) and between
rs16917302 at ZNF365 (HR=0.84; 95%CI 0.73–0.97; p=0.017) but not rs311499 at 20q13.3
(HR=1.11; 95%CI 0.94–1.31; p=0.22) and breast cancer risk for BRCA2 mutation carriers.
Analyses based on tumor histopathology showed that 19p13 variants were predominantly
associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2
mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast
cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that
rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1
(HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2 mutation carriers (HR=1.30; 95%CI
1.10–1.52; p=1.8×10−3).
Conclusions—19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes
of breast cancer among BRCA1 and BRCA2 mutation carriers.
Impact—These findings can lead to an improved understanding of tumor development and may
prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation
carriers.
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Introduction
Genome-wide association studies (GWAS) have been used to identify several loci
containing common variants that are associated (p<1.0×10−7) with breast cancer risk in the
general population. Variants from twelve of these loci have also been investigated as
modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers (1–3). While only variants
in CASP8, TOX3, 2q35, and 6q25.1 have been associated with breast cancer risk in BRCA1
mutation carriers, variants in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, 2q35, SLC4A7/
NEK10, 5p12 and 1p11.2 loci have been associated with breast cancer in BRCA2 mutation
carriers (1–3). This is consistent with the known associations between these SNPs and
estrogen receptor (ER) status of breast cancers in the general population (4).
Most recently, a GWAS of BRCA1 mutation carriers conducted through CIMBA identified
five SNPs on 19p13 that were associated with breast cancer risk for BRCA1 mutation
carriers (5). Two of these showed independent associations (rs8170 hazard ratio (HR)=1.26;
95%CI 1.17–1.35; Ptrend = 2.3×10−9 and rs2363956 HR=0.84; 95%CI 0.80–0.89;
Ptrend=5.5×10−9). Imputation analysis of the 19p13 region, using 1000 Genomes Project
data, identified several correlated SNPs with more significant associations than rs8170 and
rs2363956. The 19p13.1 locus was also found to be associated with ER negative breast
cancer (rs8170 OR=1.21, p=0.003) and triple negative breast cancer (tumors lacking
expression of ER, progesterone receptor (PR), and human epidermal growth factor receptor
2 (HER2)) (rs8170 OR=1.28, p=1.2×10−6) in the general population (5). In addition, the
19p13.1 locus has been associated with ovarian cancer in the general population (rs8170
OR=1.12; p=3.6×10−6) (6), but was not found to be associated with ovarian cancer in
BRCA1 mutation carriers (rs8170 HR=1.07; p=0.33) (5). A separate GWAS in BRCA2
mutation carriers identified two breast cancer susceptibility alleles (rs16917302 at ZNF365
(10q21.2), HR=0.75; 95%CI 0.66–0.86; p=3.8×10−5 and rs311499 at 20q13.33, HR=0.72;
95%CI 0.61–0.85; p=6.6×10−5) (7). A weakly correlated SNP at the ZNF365 locus
(rs10995190) has also been associated with breast cancer overall (OR=0.83; p=5.1 × 10−15)
and ER positive (p=4.1×10−6) but not ER negative breast cancer in the general population
(8).
Here, we genotyped more than 12,000 BRCA1 and 7,000 BRCA2 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), for the previously
genotyped variant at 19p13.1, rs8170, and one of the imputed SNPs that was found to have a
stronger association with breast cancer risk for BRCA1 mutation carriers (rs67397200). We
also genotyped SNPs at ZNF365 (rs16917302), and 20q13.3 (rs311499) in an effort to verify
these loci as risk factors for ovarian cancer and to further validate these loci as risk factors
for breast cancer in BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Subjects
All mutation carriers participated in clinical or research studies at the host institutions under
ethically approved protocols and provided written informed consent. Subjects were BRCA1
and BRCA2 mutation carriers recruited by 40 study centers in 22 countries and assembled
through the CIMBA initiative (Supplementary Table 1). The majority were recruited
through cancer genetics clinics and enrolled into national or regional studies. Others were
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identified in research studies of high-risk families, by population-based sampling of cases
and some by community recruitment. Eligibility to participate in CIMBA is restricted to
female carriers of pathogenic BRCA1 or BRCA2 mutations, defined by generally
recognized criteria (Breast Cancer Information Core), who were 18 years old or older at
recruitment. Information collected included the year of birth; mutation description
(including nucleotide position and base change); age at last follow-up; ages at breast and
ovarian cancer diagnoses; and age or date at bilateral prophylactic mastectomy. Information
was also available on the country of residence. Related individuals were identified through a
unique family identifier. Women with pathogenic mutations in both BRCA1 and BRCA2
were excluded from the current analysis. The primary analysis was restricted to women self-
reported as “white European”. Overlap of carriers between studies was evaluated by
comparing the year of birth, exact mutation description, the reported ages, and previous SNP
genotype data available within the CIMBA database. Duplicated mutation carriers were
included only once in the analysis.
Genotyping
Rs311499 at 20q13.3, rs16917302 at ZNF365 and both rs8170 and rs67397200 at 19p13.1
were genotyped using the iPLEX Mass Array platform at four genotyping centers as part of
a larger study of 24 candidate SNPs. All centers included at least 2% duplicate samples and
a random mixture of affected and unaffected carriers on each plate. Samples that failed for
five or more of the SNPs genotyped were excluded from the analysis. Studies with a SNP
call rate of <95% were excluded from the analysis of the SNP. The concordance between
duplicates had to be at least 98%. To assess the accuracy of genotyping across genotyping
centers, all centers genotyped 95 DNA samples from a standard test plate (Coriell Institute)
for all SNPs. Genotyping centers with more than one concordance failure on the test plate
for a SNP were excluded for analyses of that SNP. Deviation from Hardy-Weinberg
equilibrium (HWE) was assessed for unrelated subjects separately for each SNP and study.
The observed genotype frequencies were not significantly different from the expected under
HWE for any of the SNPs and studies. After the above exclusions, a total of 19,731 unique
mutation carriers (12,599 BRCA1 and 7,132 BRCA2) from 40 studies had an observed
genotype for at least one SNP (Supplementary Table 1).
Tumor pathology data collection
Tumor pathology data were collected from patient pathology reports, medical records,
pathology review data, tumor registry records and results from tissue microarrays. ER status
was identified as negative or positive, with immunohistochemistry scoring data and
methodology provided when available. Most studies applied a cut-off of >10% tumor cells
stained positive for ER positive status. For a small number of cases, where other scoring
methods based on the proportion and intensity of staining were applied (Allred score,
Remmele score and H-score), widely-accepted cut-offs were used. Consistency checks were
performed to validate receptor data against supplementary scoring information if provided.
Statistical analysis
The aim of the primary analysis was to evaluate the association between each genotype and
breast cancer risk. We conducted the analysis by modelling the retrospective likelihood of
the observed genotypes conditional on the disease phenotypes as previously described (9).
The phenotype of each individual was defined by age at diagnosis of breast cancer or age at
last follow-up. Individuals were censored at the earliest of age of first breast cancer
diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy or age at last
observation. Mutation carriers censored at ovarian cancer diagnosis were considered
unaffected in the analysis of breast cancer. The effect of each SNP was modelled either as a
per-allele HR (multiplicative model) or as separate HRs for heterozygotes and homozygotes.
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We used a Cox proportional-hazards model and tested the assumption of proportional
hazards by adding a “genotype×age” interaction term in order to fit models in which the HR
changed with age. We examined heterogeneity across studies by comparing models that
allowed for study-specific log-hazard ratios against models in which the same log-hazard
ratio was assumed to apply to all studies. All analyses were stratified by country of
residence and applied cohort specific breast cancer incidence rates for BRCA1 and BRCA2
(10). A robust variance-estimation approach was used to adjust for the non-independence
among related carriers.
To evaluate the evidence of replication for each of the SNPs, analyses were restricted to
mutation carriers who had not been used in any of the previous BRCA1 and BRCA2 studies.
The number of new samples used in each of the SNP analyses are shown in Supplementary
Table 2. In addition, analysis were performed using all available BRCA1 and BRCA2
carriers. The combined effects of the SNPs on breast cancer risk, were evaluated by fitting
retrospective likelihood models while allowing for linkage disequilibrium between the loci.
To test for potential effects of survival bias, prevalent cases, defined as mutation carriers
diagnosed more than five years prior to the age at recruitment, were excluded. Associations
with specific functional class of mutation were also assessed. Class 1 mutations are
predicted to undergo nonsense mediated RNA decay resulting in reduced levels of mutant
transcript while Class 2 mutations are predicted to generate stable mutant proteins (11). The
associations with breast cancer subtypes defined by the estrogen receptor (ER) status of the
tumors in BRCA1 and BRCA2 mutation carriers were assessed by an extension of the
retrospective likelihood approach that models the simultaneous effect of each SNP on more
than one tumor subtype (12). Associations with ovarian cancer risk were evaluated within a
competing risk analysis framework (13) by estimating HRs simultaneously for breast and
ovarian cancers. Since each mutation carrier was at risk of breast and ovarian cancer we
assumed that the probabilities of developing each disease were independent conditional on
the underlying genotype. In this analysis, individuals were followed to the age of the first
breast or ovarian cancer diagnosis and were considered to have developed the corresponding
disease. Individuals were censored for breast cancer at the age of bilateral prophylactic
mastectomy and for ovarian cancer at the age of bilateral oophorectomy and were assumed
to be unaffected for the corresponding disease. The remaining individuals were censored at
the age at last observation and were assumed to be unaffected for both diseases.
Results
After quality control exclusions, genotype data from 12,599 BRCA1 and 7,132 BRCA2
mutation carriers including 5,408 BRCA1 and 3,780 BRCA2 mutation carriers not studied
in the original GWAS were available for analysis. Of the BRCA1 mutation carriers, 6,390
were affected with breast cancer and 6,209 were considered unaffected in the breast cancer
analysis (censored at bilateral prophylactic mastectomy, ovarian cancer, or age at last follow
up). Similarly, among the BRCA2 mutation carriers, 3,810 were affected with breast cancer
and 3,322 were unaffected. The characteristics of these mutation carriers are shown in Table
1 and the origins of the samples are summarized in Supplementary Table 1.
The associations between breast cancer risk in BRCA1 and BRCA2 mutation carriers and
the minor alleles of rs8170 and rs67397200 (19p13.1), rs16917302 (ZNF365), and rs311499
(20q13.33) are summarized in Table 2. The minor allele of rs8170 at 19p13.1 was strongly
associated with risk of breast cancer in BRCA1 mutation carriers (HR=1.20; 95%CI 1.13–
1.28; p=8.7×10−9) but not BRCA2 mutation carriers. This result for 12,599 BRCA1
mutation carriers was consistent with the original finding in the BRCA1 GWAS using 8,363
BRCA1 mutation carriers (HR=1.26; 95%CI 1.17–1.35; p=2.3×10−9). A separate analysis
restricted to carriers not used in the BRCA1 GWAS also confirmed the association
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(HR=1.17; 95%CI 1.07–1.27; p=7.42×10−4) (Supplementary Table 2). Similarly,
rs67397200 at 19p13.1, which was imputed in the BRCA1 GWAS, was strongly associated
with breast cancer risk in BRCA1 carriers (HR=1.17; 95%CI 1.11–1.23; p=2.4×10−8) (Table
2). There was no evidence of heterogeneity in the HRs across studies for BRCA1 mutation
carriers (Figure 1). However, there was evidence that the per-allele HRs in BRCA1 mutation
carriers for rs8170 (p=0.015) and rs67397200 (p=0.007) at 19p13.1 decreased with
increasing age of diagnosis of breast cancer. Since rs8170 and rs67397200 are located in the
same region of 19p13.1 (r2=0.58), we conducted an analysis for the joint effects of these
SNPs on breast cancer risk in BRCA1 mutation carriers (n=10,173). When accounting for
haplotype structure, rs67397200 remained significant (P for inclusion=2.75×10−3) and was
retained in the model, whereas rs8170 was excluded (P for inclusion=0.18). Rs8170 and
rs67397200 were not associated with breast cancer risk for BRCA2 mutation carriers (Table
2).
Among SNPs identified from the original BRCA2 GWAS, an analysis of genotype data
from 7,132 BRCA2 mutation carriers confirmed that rs16917302 at the ZNF365 locus was
associated with a decreased risk of breast cancer (HR=0.83; 95%CI 0.75–0.93; p=7.0×10−4).
The association also replicated in the additional carriers, not previously included in the
BRCA2 GWAS (HR=0.84; 95%CI 0.73–0.97; p=0.017) (Supplementary Table 2). In
contrast, rs311499 from 20q13.3, which was associated with breast cancer risk in the
BRCA2 GWAS (HR=0.72; 95%CI 0.61–0.85; p=6.6×10−5) (7), was not associated with risk
of breast cancer in BRCA2 carriers in the overall analysis (HR=0.95; 95%CI 0.84–1.07;
p=0.36 (Table 2) nor the replication study (HR=1.11; 95%CI 0.94–1.31; p=0.22)
(Supplementary Table 2). There was no evidence for heterogeneity in the HRs across studies
for BRCA2 mutation carriers (Figure 1). HRs for rs16917302 and rs311499 did not vary by
age at diagnosis.
To determine whether the inclusion of long-term survivors influenced the results, we
repeated our analyses of the four SNPs, excluding BRCA1 and BRCA2 mutation carriers
diagnosed with breast cancer more than five years before recruitment (prevalent cases). The
strength of the associations for rs16917302 at ZNF365 (per-allele HR=0.85) for BRCA2
mutation carriers, and for rs8170 (per-allele HR=1.19) and rs67397200 at 19p13.1 (per-
allele HR=1.16) for BRCA1 mutation carriers were essentially unchanged (Supplementary
Table 3). There was no influence of mutation type for BRCA1 mutation carriers on breast
cancer risk in the associations between mutations conferring susceptibility to nonsense
mediated RNA decay (NMD) (Class 1) and missense or truncating mutations not triggering
NMD (Class 2) for any of the SNPs (Supplementary Table 4).
Breast tumors in BRCA1 mutation carriers are predominantly ER-negative (14) and rs8170
from 19p13.1 is strongly associated with ER-negative but not ER-positive breast cancer in
the general population (5). Because of these previous findings, we evaluated whether rs8170
and rs67397200 at 19p13.1, as well as rs311499 at 20q13.3 and rs16917302 at ZNF365,
were differentially associated with ER-positive and/or ER-negative tumor status in BRCA1
and BRCA2 mutation carriers. Although the stratified results suggested a slightly stronger
association for the 19p13.1 rs67397200 SNP with ER-negative disease than with ER-
positive disease in BRCA1 mutation carriers (per allele ER-negative HR=1.22; 95%CI 1.14–
1.30; p=4.4×10−9; per allele ER-positive HR=1.14; 95%CI 1.01–1.30; p=0.040), the
difference was not significant (p=0.41) (Table 3). Rs67397200, however, was associated
with ER-negative disease (per allele HR=1.29; 95%CI 1.11–1.49; p=8.7×10−4) but not ER-
positive disease (per allele HR=0.92; 95%CI 0.85–1.01; p=0.074) in BRCA2 mutation
carriers (p-heterogeneity= 1.5×10−4) (Table 3). The lack of association with rs311499 at
20q13.3 did not vary by ER-status in BRCA1 or BRCA2 mutation carriers. For BRCA2
mutation carriers, the minor allele of rs16917302 at ZNF365 was inversely associated with
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both ER-positive (per allele HR=0.86; 95%CI 0.75–0.97; p=0.016) and ER-negative tumors
(per allele HR=0.79; 95%CI 0.62–1.00; p=0.048) (p-heterogeneity=0.56) (Table 3).
However, in BRCA1 mutation carriers rs16917302 was associated with ER-positive (per
allele ER-positive HR=0.77; 95%CI 0.62–0.95; p=0.016), but not ER-negative status (p-
heterogeneity=0.028) (Table 3).
BRCA1 and BRCA2 mutations are associated with elevated risk of ovarian cancer. In this
CIMBA study 1,465 BRCA1 mutation carriers and 453 BRCA2 mutation carriers who
developed ovarian cancer were also genotyped for the four SNPs under study. To assess the
influence of these SNPs on ovarian cancer risk in BRCA1 and BRCA2 mutation carriers we
used a competing risk analysis that evaluated the associations with breast and ovarian cancer
risk simultaneously. While previous studies did not detect an association between rs8170 at
19p13.1 and ovarian cancer in BRCA1 or BRCA2 mutation carriers (5), in this competing
risk analysis with larger numbers of BRCA1 and BRCA2 mutation carriers, rs8170 was
significantly associated with ovarian cancer risk in both BRCA1 (HR=1.15; 95%CI 1.03–
1.29; p=0.015) and BRCA2 (HR=1.34; 95%CI 1.12–1.62; p=1.9×10−3) mutation carriers
(Table 4). Similarly rs67397200 at 19p13.1 was associated with ovarian cancer risk in both
BRCA1 (HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2 (HR=1.30; 95%CI 1.10–
1.52; p=1.8×10−3) mutation carriers (Table 4). Rs311499 at 20q13.3 and rs16917302 at
ZNF365 were not associated with ovarian cancer risk for either BRCA1 or BRCA2 mutation
carriers (Table 4).
Discussion
GWAS of BRCA1 and BRCA2 mutation carriers previously identified variants at 19p13.1,
ZNF365 and 20q13.3 as candidate breast cancer risk modifiers (5, 7). In this study, we
further evaluated associations between variants at these loci and both breast and ovarian
cancer in BRCA1 and BRCA2 mutation carriers. For the first time, we found that both
rs8170 and the previously imputed rs67397200 at 19p13.1 were strongly associated with
ovarian cancer in both BRCA1 and BRCA2 mutation carriers. In addition, we found that
rs8170 and rs67397200 at 19p13.1 were associated with breast cancer risk for BRCA1 and
rs16917302 at ZNF365 was associated with breast cancer in BRCA2 mutation carriers in
this replication study using an independent set of mutation carriers and in the combined
analyses of data from the original study and the replication study. In contrast, rs311499 at
20q13.3 showed no association with breast cancer in the replication study. We also report
for the first time that the BRCA1 GWAS SNP rs67397200 is associated with ER-negative
breast cancer in BRCA2 mutation carriers and that the BRCA2 GWAS SNP rs16917302 is
associated with ER-positive disease in BRCA1 mutation carriers.
The GWAS for breast cancer in BRCA1 mutation carriers originally identified significant
associations between variants at the 19p13.1 locus and risk of breast cancer. Five SNPs
including rs8170 from a 39 kb region were associated with risk of disease. In an analysis of
joint effects of these SNPs on breast cancer risk, the best model included rs8170 or
rs4808611 and rs8100241 or rs2363956 (P for inclusion=7.7×10−5 and P=6.7×10−5 for
rs8170 and rs8100241, respectively) (5), suggesting that the associations were driven by a
single causative variant partially correlated with all five SNPs. Imputation of additional
SNPs in the region from the 1000 Genome Project identified eight perfectly correlated SNPs
within a 13-kb region that were more significantly associated with breast cancer risk. Of
these, we chose rs67397200, which has an r2=0.58 with rs8170 and r2=0.37 with rs8100241/
rs2363956, for further genotyping in an effort to determine whether this SNP (or one of the
seven other highly correlated SNPs) exhibited stronger associations with breast cancer. In an
analysis of rs8170 in 11,669 and rs67397200 in 10,312 BRCA1 mutation carriers, we
observed similarly strong associations with breast cancer for BRCA1 mutation carriers. In a
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joint analysis of rs8170 and rs67397200, allowing for haplotype structure, only rs67397200
remained significant. We were unable to genotype some of the original GWAS SNPs
(rs2363956/rs8100241) in the present study and, as a consequence, could not evaluate the
joint associations with rs67397200. It is therefore still unclear whether rs67397200 accounts
solely for the association signal. The 35kb region containing rs8170 and rs67397200
includes the ABHD8 (abhydrolase domain containing 8), ANKLE1 (ankyrin repeat and
LEM domain containing 1) and C19orf62 genes. C19orf62, encodes MERIT40 (Mediator of
Rap80 Interactions and Targeting 40 kD), a BRCA1 interacting protein that forms a
complex with BRCA1-BARD1, Abraxas1, RAP80, BRCC36 and BRCC45 and is required
for recruitment and retention of the BRCA1-BARD1 ubiquitin ligase at sites of DNA
damage (15). Because alterations in MERIT40 expression or function may modify BRCA1
activity, variants in the C19orf62 locus are attractive candidate breast cancer risk modifiers.
However, since rs67397200 and the seven other imputed SNPs, that showed the most
significant associations with breast cancer risk in BRCA1 mutation carriers, are located at
the 3’ end of ANKLE1 near ABHD8 it is also possible that one of these genes rather than
C19orf62 is influenced by the underlying causative variants in this region. Further
comprehensive genotyping of other common variants and/or rare SNPs from this locus and
detailed functional studies will be required to resolve this issue.
Our GWAS for breast cancer in BRCA2 mutation carriers previously identified strong
associations between rs16917302 in the ZNF365 (dbGENE id: 22891) locus and breast
cancer (7). We have now replicated this association for BRCA2 mutation carriers.
Rs16917302 is located within intron 4 of ZNF365 and is unique to isoform C, the longest of
the four isoforms created by alternative splicing sites (16). In independent studies,
rs10995195 in ZNF365, which is 27kb upstream from and only weakly correlated (r2=0.1)
with rs16917302, has been associated with breast cancer risk (8) and with mammographic
density (17) in the general population. In addition, a cluster of SNPs located 154kb from
rs16917302 in isoform D of ZNF365 has been associated with Crohn’s disease (18–20), and
the region has also been implicated in family-based linkage analyses with uric acid
nephrolithiasis (21) and hypotrichosis (22). It is unclear whether there is genetic or biologic
linkage between these seemingly disparate phenotypes. Further fine-mapping of the ZNF365
region and functional analyses will be needed to identify the causative variants for each
phenotype and to understand the downstream biological effects.
Likewise, rs311499 at 20q13.3 was associated with breast cancer risk in BRCA2 mutation
carriers in the BRCA2 GWAS (per allele HR=0.72; 95%CI 0.61–0.85; p=6.6×10−5).
However, this association was not confirmed in the replication study described above
(HR=1.11; 95%CI 0.94–1.31; p=0.22) or in the combined analysis of the discovery and
replication stages (HR=0.95; 95%CI 0.84–1.07; p=0.36). This result was not unexpected
because the association between rs311499 and breast cancer did not reach significance
(p<0.05) in Stage 2 of the BRCA2 GWAS (HR=0.86; 95%CI 0.67–1.06; p=0.13) (7).
To further characterize the influence of the 19p13.1 and ZNF365 loci on breast cancer risk,
we assessed the strength of association with ER-negative and ER-positive breast cancer in
BRCA1 and BRCA2 mutation carriers. As reported above, rs67397200 at 19p13.1 was
associated with both ER-negative and ER-positive breast cancer in BRCA1 mutation
carriers, whereas rs8170 at 19p13.1 was only associated with ER-negative disease.
Interestingly, rs67397200 and rs8170 were also associated with ER-negative breast cancer
but not ER-positive breast cancer in BRCA2 mutation carriers. This is consistent with our
previous finding that rs8170 at 19p13.1 is more strongly associated with ER-negative than
ER-positive breast cancer in the general population (5). Given that the majority of BRCA1
breast tumors exhibit a basal breast cancer phenotype (14), it remains to be determined
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whether ER-positive basal cases account for the mild association with ER-positive disease in
BRCA1 mutation carriers.
In contrast, we found that rs16917302 in the ZNF365 locus was associated with both
ERpositive and ER-negative disease in BRCA2 mutation carriers. This was consistent with
associations for both ER-positive and ER-negative breast cancer in a recent GWAS of breast
cancer cases with a family history of the disease (8). In contrast, among BRCA1 mutation
carriers the association with breast cancer risk was restricted to ER-positive cases. This
suggests that refinement of phenotype, perhaps in specific subpopulations, may result in
detection of previously hidden associations.
Ovarian cancer is an important component of the cancer phenotype in both BRCA1 and
BRCA2 mutation carriers. Because breast and ovarian cancer can occur in the same
mutation carriers, it has been suggested that susceptibility SNPs common to breast and
ovarian cancer may exist in these populations. However, to date none of the SNPs associated
with breast cancer risk in BRCA1 or BRCA2 mutation carriers have been associated with
ovarian cancer risk. Similarly, SNPs in the BCN2 locus that are associated with ovarian
cancer risk in BRCA1 and BRCA2 mutation carriers are not associated with breast cancer
risk (13). Furthermore, in the general population, only SNPs in the 8q24 locus are known to
influence both breast and ovarian cancer, and these appear to be independent disease-
specific effects (23). Thus, the recent finding that SNPs at 19p13.1 were associated with
breast cancer in BRCA1 mutation carriers (5) and also with ovarian cancer in the general
population (6) raised the possibility that a locus with common influences on breast and
ovarian cancer does exist. However, the BRCA1 GWAS failed to detect any association for
19p13.1 SNPs with ovarian cancer among BRCA1 mutation carriers (843 ovarian cases)
(HR=1.07; 95%CI 0.93–1.24; p=0.33) (5). Here we re-evaluated associations between
19p13.1 SNPs and ovarian cancer using larger numbers of BRCA1 (n=1312) and BRCA2
(n=429) carriers diagnosed with ovarian cancer. Rs67397200 at 19p13.1 was associated with
ovarian cancer risk in both BRCA1 (HR=1.16; 95%CI 1.05–1.29; p=3.8×10−4) and BRCA2
(HR=1.30; 95%CI 1.10–1.52; p=1.8×10−3) mutation carriers. The magnitude of the effect on
ovarian cancer risk in BRCA1 carriers (HR=1.16) was similar to that observed for breast
cancer. This is the first locus found to influence both breast and ovarian cancer risk in either
BRCA1 or BRCA2 mutation carriers.
Including the SNPs from the present study, six loci are now known to modify the risk of
breast cancer for BRCA1 mutation carriers (CASP8, TOX3, 2q35, 6q25.1, 19p13, and
ZNF365 (ER-positive disease only)) (1–3, 5, 10, 24) and ten loci are known to modify the
risk of breast cancer for BRCA2 mutation carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35,
SLC4A7, 5p12, ZNF365, 1p11.2 and 19p13.1 (ER-negative only)) (5, 7, 10, 24). Taken
together, these SNPs result in large variation in the absolute risk of breast cancer for BRCA1
and BRCA2 mutation carriers and may further improve our ability to provide individualized
risks of breast cancer for BRCA1 and BRCA2 mutation carriers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Forest plots of the associations by country of residence of BRCA1 and BRCA2 mutation
carriers with breast cancer risk overall
(A–C) Squares indicate the country specific per-allele HR estimates for SNPs (A) rs8170 for
BRCA1 mutation carriers, (B) rs67397200 for BRCA1 mutation carriers and (C)
rs16917302 for BRCA2 mutation carriers. The area of the square is proportional to the
inverse of the variance of the estimate. Horizontal lines indicate 95% Confidence Intervals
(CIs).
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Table 1
Summary characteristics for the 19,731 eligible BRCA1 and BRCA2 mutation carriers* used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast
Cancer
Unaffected Breast
Cancer
Number 6209 6390 3322 3810
Person-Years follow-up 264903 263068 147053 168201
Median Age at Censure (IQR1) 42 (34–50) 40 (34–47) 43 (34–53) 43 (37–50)
Age at Censure, N (%)
<30 1189 (19.2) 691 (10.8) 611 (18.4) 306 (8.0)
30–39 1661 (26.8) 2445 (38.3) 834 (25.1) 1141 (30.0)
40–49 1765 (28.4) 2191 (34.3) 865 (26.0) 1394 (36.6)
50–59 1058 (17.0) 812 (12.7) 566 (17.0) 687 (18.0)
60–69 380 (6.1) 198 (3.1) 302 (9.1) 226 (5.9)
70+ 156 (2.5) 53 (0.8) 144 (4.3) 56 (1.5)
Year of birth, N (%)
<1920 28 (0.5) 30 (0.5) 23 (0.7) 44 (1.2)
1920–29 131 (2.1) 196 (3.1) 99 (3.0) 167 (4.4)
1930–39 369 (5.9) 516 (8.1) 232 (7.0) 430 (11.3)
1940–49 832 (13.4) 1341 (21.0) 458 (13.8) 896 (23.5)
1950–59 1409 (22.7) 1989 (31.1) 691 (20.8) 1160 (60.5)
1960–69 1703 (27.4) 1666 (26.1) 902 (27.2) 868 (22.8)
1970+ 1737 (28.0) 652 (10.2) 917 (27.6) 245 (6.4)
Mutation Class, N (%)
Class 12 4063 (65.4) 3878 (60.7) 3114 (93.7) 3520 (92.4)
Class 22 1780 (28.7) 1973 (30.9) 72 (2.2) 100 (2.6)
Other 366 (5.9) 539 (8.4) 136 (4.1) 190 (5.0)
1
IQR: Interquartile range
2See methods for definitions
*Carriers of self reported European ancestry only.
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